1. Piper Sandler Upgrades Biogen to Overweight, Citing Apellis Buyout Potential
Investment firm Piper Sandler has upgraded Biogen's stock rating to Overweight, a move directly tied to the potential acquisition of Apellis Pharmaceuticals. This analyst action signals a significant shift in sentiment, placing a high-stakes strategic bet on Biogen's future direction. The upgrade is not based on curren...